Compare Lumentum (LITE) vs uniQure N.V. Ordinary Shares (QURE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Lumentum vs uniQure N.V. Ordinary Shares — how do they compare? Lumentum trades at $867.89 (market cap $89.49B), while uniQure N.V. Ordinary Shares trades at $20.67 (market cap $1.48B). The key difference: Lumentum is far larger — about 60.5× uniQure N.V. Ordinary Shares's market cap, and Lumentum is more actively traded (3,978,382 versus 2,488,780). Which is the better fit depends on your goals — on Pluang, investors hold Lumentum for 5 Days and uniQure N.V. Ordinary Shares for 0 Days on average.
| LITE | QURE | |
|---|---|---|
Market Cap | $89.49B | $1.48B |
Volume | 3,978,382 | 2,488,780 |
Sector | Technology | Health |
52-Week High | $1.13K | $70.59 |
52-Week Low | $156.57 | $9.03 |
Typical Hold Time | 5 Days | 0 Days |
Enterprise Value | $88.43B | $728.62M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Lumentum (LITE) trades at $987.99, down 0.75% today amid a sector-wide sell-off in optical stocks, yet maintains a bullish technical trend with strong analyst support. The company reported three consecutive quarterly earnings beats, with Q3 2026 results pending, and demonstrates robust revenue growth projections fueled by AI data center demand, though profitability metrics show significant losses. Recent news highlights capacity sold out through early 2029, underscoring strong demand but also supply constraints.
Outlook is positive due to explosive AI-driven demand and a solid backlog, but risks include high valuation multiples, negative net income margin, and sensitivity to AI funding sentiment. Institutional ownership and analyst consensus lean bullish, with a price target of $1,110, suggesting potential upside if execution meets expectations.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Lumentum
Lumentum develops photonic products, including optical components, transceivers, and lasers. Its technologies support data centers, communications networks, industrial manufacturing, and sensing applications.
Read more on LITE →About uniQure N.V. Ordinary Shares
uniQure N.V. is a biotechnology company that develops gene therapies for rare and severe genetic diseases, marketing HEMGENIX for hemophilia B and advancing its AAV-based miQURE platform in programs such as AMT-130 for Huntington's disease.
Read more on QURE →
